Research progress on comprehensive treatment of locally advanced pancreatic cancer

Abstract

CLC Number:

R735.9

QIAN Lihan, SHN Baiyong. Research progress on comprehensive treatment of locally advanced pancreatic cancer[J]. Journal of Surgery Concepts & Practice, 2020, 25(05): 442-446.

References32

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
[2]	Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic Adenocarcinoma, Version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):202-210.
[3]	Fogelman D, Sugar EA, Oliver G, et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma[J]. Cancer Chemother Pharmacol, 2015, 76(3):489-498.
[4]	Rahma OE, Duffy A, Liewehr DJ, et al. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials[J]. Ann Oncol, 2013, 24(8):1972-1979. doi:10.1093/annonc/mdt166pmid:23670093
[5]	Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15(6):2403-2413. doi:10.1200/JCO.1997.15.6.2403pmid:9196156
[6]	von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gem-citabine[J]. New Engl J Med, 2013, 369(18):1691-1703.
[7]	Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825.
[8]	Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort[J]. Ann Surg Oncol, 2015, 22(1):295-301. doi:10.1245/s10434-014-3898-9pmid:25037971
[9]	Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis[J]. Lancet Oncol, 2016, 17(6):801-810.
[10]	Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial[J]. Lancet Oncol, 2013, 14(4):317-326. doi:10.1016/S1470-2045(13)70021-4pmid:23474363
[11]	Akahori T, Sho M, Yanagimoto H, et al. Phase Ⅱ study of the triple combination chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma[J]. Oncologist, 2019, 24(6):749-e224.
[12]	Sultana A, Tudur Smith C, Cunningham D, et al. Syste-matic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J]. Br J Cancer, 2007, 96(8):1183-1190.
[13]	Hammel P, Huguet F, van Laethem J, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib[J]. JAMA, 2016, 315(17):1844-1853.
[14]	Faris JE, Blaszkowsky LS, Mcdermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience[J]. Oncologist, 2013, 18(5):543-548.
[15]	Cattaneo GM, Passoni P, Longobardi B, et al. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma[J]. Radiother Oncol, 2013, 108(1):66-71.
[16]	Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer[J]. Pract Radiat Oncol, 2016, 6(2):78-85.
[17]	Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):242-249.
[18]	Song Y, Yuan Z, Li F, et al. Analysis of clinical efficacy of CyberKnife^®treatment for locally advanced pancreatic cancer[J]. Onco Targets Ther, 2015, 8:1427-1431.
[19]	Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531(7592):47-52.
[20]	Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma[J]. Cancer, 2007, 109(8):1561-1569.
[21]	Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study[J]. Ann Oncol, 2017, 28(10):2429-2435. doi:S0923-7534(19)34947-6pmid:28961832
[22]	Waddell N, Pajic M, Patch A, et al. Whole genomes redefine the mutational landscape of pancreatic cancer[J]. Nature, 2015, 518(7540):495-501.
[23]	Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancrea-tic cancer: outcomes from the CONKO-003 trial[J]. J Clin Oncol, 2014, 32(23):2423-2429.
[24]	Watkins JA, Irshad S, Grigoriadis A, et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers[J]. Breast Cancer Res, 2014, 16(3):211.
[25]	Shroff RT, Hendifar A, Mcwilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation[J]. JCO Precis Oncol, 2018, 2018:10.1200/PO.17.00316. doi: 10.1200/PO.17.00316. doi:10.1200/PO.17.00316 URL
[26]	Hammel P, Kindler HL, Reni M, et al. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib[J]. Ann Oncol, 2019, 30(12):1959-1968. doi:S0923-7534(20)32559-Xpmid:31987299
[27]	Sahin IH, Askan G, Hu ZI, et al. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?[J]. Ann Oncol, 2017, 28(12):2950-2961. doi:10.1093/annonc/mdx503pmid:28945842
[28]	Sahin IH, Lowery MA, Stadler ZK, et al. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(8):893-905.
[29]	Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin(CRS-207) boost vaccines for metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(12):1325-1333. doi:10.1200/JCO.2014.57.4244
[30]	Chung MJ, Park JY, Bang S, et al. Phase Ⅱ clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer[J]. Cancer Immunol Im-munother, 2014, 63(9):939-946.
[31]	Balaban EP, Mangu PB, Yee NS. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary[J]. J Oncol Pract, 2017, 13(4):265-269. doi:10.1200/JOP.2016.017376pmid:28399382
[32]	栗志磊, 范新奇, 包伟, 等. 局部进展期胰腺癌的诊治策略进展[J]. 中华肝胆外科杂志, 2018, 24(11):789-792.

Research progress on comprehensive treatment of locally advanced pancreatic cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References32

Related Articles15

Recommended Articles

Metrics

Comments

[1]	ZHANG Hongzhan, ZHANG Kai.Current status and prospect of endoscopic photodynamic therapy for unresectable extrahepatic cholangiocarcinoma and ampullary carcinoma[J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 316-320.
[2]	GAO Pan, CAI Yunqiang, PENG Bing.Function-preserving laparoscopic resection of pancreatic head and duodenal papilla tumors[J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 190-196.
[3]	YU Lan, ZHANG Yongyi, HUANG Lei, WAN Xin, JIANG Shengyao, TANG Sijing, ZHANG Jun, HU Weiguo.Risk factors of severe postoperative complications in elderly patients with pancreaticoduodenectomy[J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 139-146.
[4]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 1-5.
[5]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 6-10.
[6]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 14-18.
[7]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 19-21.
[8]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 25-29.
[9]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 30-33.
[10]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 34-38.
[11]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 42-45.
[12]	YANG Chunxue, XU Haimin, DA Qian.Clinicopathological features of pancreatic intraductal oncocytic papillary neoplasm: a report of 5 cases[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 52-57.
[13]	XU Yu, ZHANG Junfeng, HUA Rong.Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 83-86.
[14]	LUO Danyang, GAO Yiming.Study on oral microflora related to pancreatic cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 84-86.
[15]	DING Fangmi, LIU Zhendong.Forkhead box D1 promotes invasion and metastasis of pancreatic cancer via extracellular signal-regulated kinase pathway[J]. Journal of Surgery Concepts & Practice, 2020, 25(06): 486-492.